Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9244MR)

This product GTTS-WQ9244MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9244MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3971MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ4499MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ14276MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ2764MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ2290MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ7503MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ5481MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ7580MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW